Retatrutide's Phase 3 results surpass both by a margin that's clinically meaningful, not just statistically so
& Belzung, C
Furthermore, in a phase 2 trial involving patients with obesity, the least squares mean percentage change in body weight at 24 weeks was 17.5 % for retatrutide 12 mg, compared with 1.6 % in the placebo group, and at 48 weeks it was 24.2 % for retatrutide 12 mg, compared with 2.1 % in the placebo group
Interest in retatrutide is growing rapidly in Thailand, though availability remains limited compared to semaglutide and tirzepatide
Anti-aging, treat diseases and recovery therapies Experimental or off-label use Despite these claims, the federal law does not classify these peptides as dietary supplements
FDA nonclinical toxicology review (2023-2024) flagged DNA damage in pituitary cells and injection-site necrosis in animal studies, plus immunogenicity and impurity risks from compounded material, alongside GH/IGF-1-axis effects such as fluid retention, joint discomfort, flushing, and headache reported by users